Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH509 in NASH/NAFLD
NCT05784779Phase 2Unknown
- Sponsor
- 1Globe Biomedical
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) comparing GH509 with Placebo (2 arms). Primary endpoints: Recommended Phase II Dose at 12 weeks and Change in liver fat content as assessed by MRI-PDFF at 12 weeks. Status: unknown.
02
Drugs
GH509
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05784779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784779.